Table 1.
Basic characteristics of all the included studies regarding PARPs for this meta-analysis.
| Organ | Authors | Year | Country | Ethnicity | Study Period | Cancer Type/TNM Stage | Patients No. |
Average Age (Range) |
Median f/u (Years) | PARP Phenotype | Chemo Regimen | Detection Method | Hazard Ratio (CI 95%) |
NOS Score |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Breast | Gonclaves [10] |
2011 | France | Caucasian | NA | IDC/ILC/MC/ others Stage I-IIIB |
2485 | NA | 8 | PARP-1 | Adj. Ant/Tax/CMF |
PCR | OS: 1.16 (1.04–1.29) | 8 |
| Minckwitz [16] |
2011 | Germany | Caucasian | 2001–2005 | IDC/ILC/ others Stage IIA-IIIB |
638 | NA | 4.8 | PARP | Neoadj. Ant/Tax |
IHC | OS: 1.76 (0.87–3.50) DFS: 1.44 (1.88–2.36) |
8 | |
| Rojo [17] |
2012 | Spain | Caucasian | 1998–2000 | IDC/ILC/ others NA |
330 | 58 (26–90) |
8.5 | PARP-1 | Adj. CMF/horm |
IHC | OS: 1.82 (1.32–2.52) DFS: 10.05(5.42–18.66) |
8 | |
| Donizy [9] |
2014 | Poland | Caucasian | 1993–1994 | IDC Stage IIA-IIB |
83 | 55.2 | 15 | PARP-1 | Neoadj. CMF/Ant |
IHC | OS: 2.81 (1.12–7.03) | 7 | |
| Aiad (1) * [7] |
2015 | Egypt | Caucasian | 2008–2012 | IDC Stage IIIB |
84 | 53 (29–86) |
NA | PARP-1 | Neoadj.FEC | IHC | OS: 0.40 (0.08–2.05) | 7 | |
| Aiad (2) * [7] |
2015 | Egypt | Caucasian | 2008–2012 | IDC Stage IIIB |
84 | 53 (29–86) |
NA | PARP-1 | Neoadj.FEC | IHC | OS: 0.21 (0.04–1.00) | 7 | |
| Green [11] |
2015 | UK | Caucasian | 1989–2004 | OBC Stage I–III |
1269 | 55 | NA | PARP-1 | NA | IHC | DFS: 1.32 (0.99–1.77) | 7 | |
| Park [14] |
2015 | South Korea | Asian | 1997–2003 | IC/ILC Stage I–IV |
192 | 47 (22–73) |
11.2 | PARP-1 | Adj. Ant/Tax/CMF |
IHC | OS: 3.64 (1.88–7.05) DFS: 1.95 (1.44–3.34) |
8 | |
| Zhai [15] |
2015 | China | Asian | 2007–2012 | IDC/ILC Stage I-IIB |
198 | 53 (29–70) |
4 | PARP-1 | Neoadj. Ant/Tax |
IHC | OS: 4.30 (0.74–25.00) PFS: 1.18 (1.03–1.35) |
8 | |
| Mazzotta [13] |
2016 | Italy | Caucasian | 1998–2012 | IDC/others Stage I-IIIB |
114 | 53 | 4.8 | PARP-1 | Adj. Horm/chemo |
IHC | OS: 1.59 (1.40–181.19) DFS: 6.61 (1.52–28.80) |
8 | |
| Deng [8] |
2017 | China | Asian | 2000–2012 | TNBC Stage I-IIIB |
118 | 51.6 (25–81) |
6.2 | PARP-1 | Adj. Ant/Tax |
IHC | DFS: 2.23 (1.20–4.13) | 8 | |
| Mangia [12] |
2017 | Italy | Caucasian | 1996–2012 | IDC/ILC/ others NA |
308 | 51 (24–80) |
6.1 | PARP-1 | NA | IHC | OS: 1.71 (0.36–8.16) DFS: 0.78 (0.32–1.91) |
8 | |
| Song [19] |
2017 | China | Asian | 2005–2010 | IDC, LC, MC Stage I-IV |
547 | 51 (20–82) |
9.8 | PARP-3 | Adj. CAF/CEFD | IHC | OS: 1.71 (0.93–3.15) DFS: 1.94 (1.19–3.19) |
8 | |
| Siraj [18] |
2018 | Saudi Arabia | Caucasian | 1990–2011 | IDC, ILC, MC Stage I–IV |
1008 | 45 (39–54) |
4 | PARP | NA | IHC | OS: 1.43 (1.01–2.04) | 8 | |
| Ovary | Brustmann [22] |
2007 | Austria | Caucasian | 1985–1996 | SOC Stage I–III |
50 | 64 | NA | PARP | Adj. PBC | IHC | DFS: 1.16 (1.02–1.31) | 7 |
| Barnett [21] |
2010 | USA | Caucasian | 1995–2003 | SOC Stage I–IV |
186 | 61 (19–86) |
NA | PARP | Adj. PBC | IHC | OS: 0.71 (0.50–0.99) PFS: 0.36 (0.09–1.51) |
7 | |
| Gan (1) * [23] |
2013 | UK | Caucasian | 1991–2007 | SOC Stage I–IV |
174 | 61 (36–86) |
NA | PARP-1 | Adj. PBC | IHC | OS: 1.90 (1.10–3.20) PFS: 2.59 (1.12–6.00) |
7 | |
| Gan (2) * [23] |
2013 | UK | Caucasian | 1991–2007 | SOC Stage I–IV |
174 | 61 (36–86) |
NA | C-PARP-1 | Adj. PBC | IHC | OS: 1.63 (1.04–2.57) PFS: 1.20 (1.00–1.44) |
7 | |
| Ali [20] |
2019 | UK | Caucasian | 1997–2010 | SOC Stage I–IV |
525 | NA | NA | PARP-1 | Adj. PBC | IHC | PFS: 1.13 (0.83–1.54) | 7 | |
| Molnar [24] |
2020 | Hungary | Caucasian | 2011–2017 | SOC Stage IIIA-IIIB |
86 | 57 | 2.7 | PARP | Adj. Pac/Carbo | IHC | OS: 11.74 (1.30–105.63) PFS: 13.52 (1.86–98.04) |
8 | |
| Molnar [25] |
2021 | Hungary | Caucasian | 2011–2019 | SOC Stage IIIA-IIIB |
104 | 57.9 | 2.8 | PARP | Adj. Pac/Carbo | IHC | OS: 1.14 (1.03–1.27) PFS: 1.05 (1.02–1.07) |
8 | |
| Lung | Kim [27] |
2014 | South Korea | Asian | 2008–2012 | SCLC Stage I–III |
79 | 62 | 1.6 | PARP-1 | Neoadj. Eto/Cis/Carbo | IHC | PFS: 0.49 (0.26–0.91) | 8 |
| Xie [28] |
2014 | China | Asian | 2008–2010 | NSCLC Stage I–IV |
111 | 63 (43–81) |
NA | PARP-1 | NA | IHC | OS: 2.29 (1.08–4.85) | 7 | |
| Michels [26] |
2015 | France | Caucasian | 1994–2002 | NSCLC Stage I-II |
225 | 64 (40–82) |
10.03 | PARP | NA | IHC | OS: 1.99 (1.04–3.76) DFS: 1.71 (0.95–3.62) |
8 | |
| Liver | Lin [29] |
2016 | China | Asian | 2005–2008 | HCC Stage I–IV |
145 | 45.4 | NA | PARP-2 | NA | IHC | OS: 4.56 (2.12–9.79) | 7 |
| Yu [30] |
2019 | China | Asian | NA | HCC Stage I–IV |
298 | NA | NA | PARP-1 | NA | PCR | OS: 2.43 (1.17–5.07) DFS: 2.11 (1.46–3.04) |
7 | |
| Soft tissue |
Li [31] |
2016 | China | Asian | 1996–2012 | SC NA |
50 | 55.1 (24–90) |
5.4 | PARP-1 | NA | IHC | DFS: 1.07 (1.02–1.14) | 7 |
| Kim [37] |
2016 | South Korea | Asian | 1998–2013 | STS Stage I–IV |
105 | NA | 15 | PARP-1 | Adj. chemo | IHC | DFS: 2.78 (1.70–4.55) | 8 | |
| Brain | Murnyák [32] |
2017 | Hungary | Caucasian | 2006–2014 | Glioma Stage II-IV |
135 | 60.5 (21–89) |
NA | PARP-1 | NA | PCR | OS: 1.11 (1.01–1.22) | 7 |
| Oesophagus | Yamamoto [33] |
2017 | Japan | Asian | 1998–2011 | SCC IA-IVB |
86 | NA | 3.5 | PARP-1 | NA | IHC | OS: 2.39 (1.29–4.44) | 8 |
| Pancreas | Klauschen [35] |
2012 | Germany | Caucasian | NA | PDAC Stage I–IV |
178 | NA | NA | PARP | NA | IHC | OS: 0.63 (0.41–0.96) | 7 |
| Skin | Donizy [36] |
2020 | USA | Caucasian | 1989–2018 | MM Stage I–IV |
192 | 65 | 1.9 | PARP-1 | NA | IHC | OS:1.53 (1.01–2.33) | 8 |
| Stomach | Liu [34] |
2016 | China | Asian | NA | GC stage I–IV |
564 | 60 (29–82) |
5.5 | PARP-1 | NA | IHC | OS: 1.64 (0.99–2.71) DFS: 1.35 (0.86–2.12) |
8 |
Abbreviations: PARP: nuclear and cytoplasmic poly(ADP-ribose) polymerases; NOS: Newcastle–Ottawa scale; NA: not available; IHC: immunohistochemistry; PCR: polymerase chain reaction; HR: hazard ratio; OS: overall survival; DFS: disease free-survival; PFS: progression free-survival; IDC: invasive ductal carcinoma; IC: invasive carcinoma; ILC: invasive lobular carcinoma; MC: mucinous carcinoma; TNBC: triple-negative breast cancer; FEC: fluorouracil, epirubicin, and cyclophosphamide; Ant/Tax: anthracycline/taxane; Horm: hormonal therapy; CMF: cyclophosphamide, methotrexate, and 5-fluorouracil; Chemo: chemotherapy; CAF/CEFD: cyclophosphamide/doxorubicin or epirubicin/5-fluorouracil and docetaxel; C-PARP: cleaved PARP; SOC: serous ovarian carcinoma (include serous ovarian carcinoma, serous cystadenocarcinoma, endometrioid, clear cell carcinoma, mucinous cystadenocarcinoma, mixed, other, and unknown); Carbo/Cyclo: carboplatin and cyclophosphamide; Pac: Paclitaxel; PBC: platinum-based chemotherapy; SCLC: small cell lung cancer; Eto/Cis/Carbo: etoposide/cisplatin/carboplatin; NSCLC: non-small cell lung cancer; HCC: hepatocellular carcinoma; SCC: squamous cell carcinoma; PDAC: pancreatic ductal adenocarcinoma; MM: mucosal melanomas; SC: sacral chordoma; STS: soft tissue sarcoma; GC: gastric cancer; and Adj.: adjuvant. Note: * Aiad (1): target cytoplasmic PARP, Aiad (2): target nuclear PARP, Gan (1), Target Nuclear PARP-1, and Gan (2): target nuclear cleaved PARP-1.